ASCO 2025 Preview: Key Oncology Highlights to Watch

ASCO 2025 at a glance

Prepare for ASCO 2025 with LucidQuest’s concise preview, highlighting must-see sessions and key trends in oncology, from breakthrough cancer treatments to cutting-edge uses of AI in clinical practice.

📅 Build your schedule around the topics that interest you. 📥 Download the ASCO 2025_Preview_by_LucidQuest

Dive deeper

Key Topics From ASCO 2025 Scientific Presentations

Lung Cancer

• Benmelstobart + chemo → anlotinib tops tislelizumab.

• HLX07 + serplulimab active in EGFR-high sqNSCLC.

• Bispecifics & vaccines move to pivotal trials. 🫁🚀

GI / GU

• Allo-316 CAR-T hits ccRCC.

• Epigenetic priming boosts PSMA-RLT.

• #AI steers #NMIBC management. 🍎🎯

Pediatric Oncology

• Naxitamab + HITS/ICE lifts r/r neuroblastoma responses.

• Luveltamab ADC moves in #AML.

• ctDNA WGS personalizes sarcoma tracking. 🩺

Head & Neck

• Brentuximab + pembrolizumab in mHNSCC.

• Chemo-IO shrinkage enables function-saving surgery.

• Nimotuzumab + RT lowers tox in NPC. 🗣️

Breast Cancer

• Olaparib/carboplatin ups pCR in BRCA1/2 eTNBC.

• CE/BZA cuts ER+ DCIS proliferation.

• APBI halves high-grade toxicity vs WBI. 🎗️

Endocrine Resistance

• Elacestrant mixes safely.

• RLY-2608 hits PIK3CA.

• Inavolisib + palbociclib + fulvestrant extends OS. 💊🔄

HER2+

• Zongertinib & BAT8010 show ORR to 58%.

• BCI testing alters extended ET in 41% of cases.

• ⁶⁸Ga-FAPI PET guides brain-mets care. 🧩🎯

TNBC

• Camrelizumab combos post ORR 71%.

• SHR-A1811 + adebrelib 6-mo PFS 86%.

• CXCL9/10 signal pembrolizumab benefit. 🥊💥

Prostate

• SBRT + ADT gives PSA < 0.1 in 80%.

• LuPSMA + ipilimumab/nivolumab lifts PFS but with ↑ tox.

• Pasritamig bispecific posts PSA50 42%. 🔬🛡️

Biomarkers

• PD-L1 IC-high/TPS-low NSCLC gains from nivolumab + ipilimumab.

• ctDNA MRD flags high-risk peri-NSCLC.

• Neutrophils predict mesothelioma ICI response. 🏷️🧪

Artificial Intelligence and Machine Learning at ASCO 2025

Evidence AI

• ASCOmind reviews myeloma abstracts in <5 min, streamlining updates. ⚡️📚

LLM Tools

• Llama 3.1 tags AEs at 98% sensitivity; Synapsis screens trials 170× faster. 🤖📝

Predictive EHR

• XGBoost + LLM notes cut 30-day admits by 22%, saving beds. 🏥💡

Smart Imaging

• DL MRI grades ICANS; ultrasound pCR prediction hits 94% sensitivity. 🖥️🔍

Digital Pathology

• AI HER2 score beats pathology; local fine-tuned DL boosts ER call AUROC 0.85. 🔬📈

Radiomics

• 3-D model predicts PD-L1 (F1 76%); spatial AI biomarker tops PD-L1 alone. 📊🎯

CAR-T Risk

• XGBoost links malnutrition to 3× mortality in CAR-T cohorts. 🍽️⚠️

Serum AI

• Random forest detects RCC via serum (AUC 0.76); CSF gene set predicts CNS mets (AUC 0.886). 🩸🔎

Drug Discovery

• AI docking finds USP21 inhibitors for NSCLC immune evasion. 💻🧪